LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

About Study 19

Efficacy

Adding Lynparza to the treatment paradigm allows women living with BRCAm platinum-sensitive relapsed high-grade serous ovarian cancer to actively extend PFS.3

PFS

+6.9 MONTH IMPROVEMENT IN MEDIAN PFS OVER PLACEBO3

Maintenance treatment with Lynparza has demonstrated a significant benefit for BRCAm platinum-sensitive relapsed high-grade serous ovarian cancer patients, improving PFS by a median of 6.9 months vs placebo (HR 0.18; 95% CI 0.10-0.31; p<0.00001; median PFS 11.2 vs 4.3 months).3, 4

A comparison chart between Placebo and Lynparza
A comparison chart between Placebo and Lynparza

Adapted with permission.3

82% reduction in the risk of disease progression or death compared to placebo. (HR 0.18; 95% CI 0.10-0.31; p<0.00001; median PFS 11.2 vs 4.3 months).3, 4

A comparison chart between Placebo and Lynparza
A comparison chart between Placebo and Lynparza

Adapted with permission.3